Zacks Investment Research upgraded shares of Chimerix, Inc. (NASDAQ:CMRX) from a hold rating to a buy rating in a research note published on Wednesday, August 9th. The brokerage currently has $5.25 price target on the biopharmaceutical company’s stock.
According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “
CMRX has been the topic of several other reports. Cowen and Company reiterated a hold rating and issued a $6.00 target price on shares of Chimerix in a research note on Friday, April 28th. FBR & Co reiterated a hold rating and issued a $7.00 target price on shares of Chimerix in a research note on Monday, May 1st.
Chimerix (NASDAQ:CMRX) traded down 1.14% during trading on Wednesday, hitting $4.35. The company had a trading volume of 140,130 shares. Chimerix has a 52-week low of $3.66 and a 52-week high of $6.64. The stock’s market capitalization is $204.65 million. The firm’s 50 day moving average is $4.98 and its 200-day moving average is $5.41.
Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.05. The company had revenue of $0.68 million for the quarter, compared to analysts’ expectations of $1.28 million. Chimerix had a negative net margin of 1,514.27% and a negative return on equity of 24.68%. On average, equities analysts forecast that Chimerix will post ($1.63) earnings per share for the current year.
A number of institutional investors have recently made changes to their positions in the company. State Street Corp raised its position in shares of Chimerix by 2.6% in the fourth quarter. State Street Corp now owns 751,031 shares of the biopharmaceutical company’s stock worth $3,453,000 after buying an additional 18,688 shares during the period. TFS Capital LLC bought a new position in shares of Chimerix during the first quarter worth about $684,000. Bank of Montreal Can raised its position in shares of Chimerix by 3.8% in the first quarter. Bank of Montreal Can now owns 39,300 shares of the biopharmaceutical company’s stock worth $251,000 after buying an additional 1,448 shares during the period. Victory Capital Management Inc. bought a new position in shares of Chimerix during the first quarter worth about $776,000. Finally, Nationwide Fund Advisors raised its position in shares of Chimerix by 5.9% in the first quarter. Nationwide Fund Advisors now owns 35,573 shares of the biopharmaceutical company’s stock worth $227,000 after buying an additional 1,977 shares during the period. 64.98% of the stock is currently owned by institutional investors and hedge funds.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with our FREE daily email newsletter.